Arizona State Retirement System Has $1.37 Million Stake in 10x Genomics, Inc. (NASDAQ:TXG)

Arizona State Retirement System lifted its position in shares of 10x Genomics, Inc. (NASDAQ:TXG) by 3.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 24,562 shares of the company’s stock after buying an additional 813 shares during the period. Arizona State Retirement System’s holdings in 10x Genomics were worth $1,374,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. Raymond James & Associates boosted its position in 10x Genomics by 19.3% during the 1st quarter. Raymond James & Associates now owns 53,009 shares of the company’s stock worth $4,032,000 after acquiring an additional 8,570 shares during the last quarter. US Bancorp DE increased its stake in 10x Genomics by 39.6% in the 1st quarter. US Bancorp DE now owns 9,711 shares of the company’s stock valued at $739,000 after buying an additional 2,753 shares during the last quarter. PNC Financial Services Group Inc. lifted its position in 10x Genomics by 617.9% during the 1st quarter. PNC Financial Services Group Inc. now owns 2,046 shares of the company’s stock worth $155,000 after buying an additional 1,761 shares in the last quarter. MetLife Investment Management LLC bought a new stake in 10x Genomics during the 1st quarter worth about $416,000. Finally, BlackRock Inc. boosted its stake in shares of 10x Genomics by 14.2% during the 1st quarter. BlackRock Inc. now owns 9,156,992 shares of the company’s stock worth $696,572,000 after buying an additional 1,138,358 shares during the last quarter. 84.68% of the stock is currently owned by institutional investors.

10x Genomics Price Performance

10x Genomics stock opened at $34.55 on Friday. The stock’s fifty day moving average price is $41.43 and its two-hundred day moving average price is $43.33. 10x Genomics, Inc. has a one year low of $33.79 and a one year high of $63.57. The firm has a market cap of $4.12 billion, a PE ratio of -15.92 and a beta of 1.90.

10x Genomics (NASDAQ:TXG) last released its quarterly earnings results on Thursday, February 15th. The company reported ($0.41) EPS for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.05). 10x Genomics had a negative net margin of 41.17% and a negative return on equity of 28.82%. The company had revenue of $183.98 million during the quarter, compared to the consensus estimate of $182.73 million. During the same quarter last year, the firm posted ($0.15) EPS. The company’s quarterly revenue was up 17.8% on a year-over-year basis. Sell-side analysts expect that 10x Genomics, Inc. will post -1.47 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on TXG shares. Stifel Nicolaus cut their price objective on 10x Genomics from $68.00 to $63.00 and set a “buy” rating for the company in a report on Friday, February 16th. Barclays lowered their price objective on shares of 10x Genomics from $55.00 to $45.00 and set an “overweight” rating on the stock in a research note on Wednesday. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $60.88.

Insider Transactions at 10x Genomics

In related news, CEO Serge Saxonov sold 4,000 shares of 10x Genomics stock in a transaction on Tuesday, January 16th. The shares were sold at an average price of $45.24, for a total transaction of $180,960.00. Following the completion of the transaction, the chief executive officer now owns 856,381 shares of the company’s stock, valued at $38,742,676.44. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In other 10x Genomics news, CFO Justin J. Mcanear sold 1,865 shares of the stock in a transaction that occurred on Thursday, February 22nd. The stock was sold at an average price of $46.34, for a total transaction of $86,424.10. Following the transaction, the chief financial officer now directly owns 95,240 shares in the company, valued at approximately $4,413,421.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Serge Saxonov sold 4,000 shares of 10x Genomics stock in a transaction on Tuesday, January 16th. The shares were sold at an average price of $45.24, for a total transaction of $180,960.00. Following the completion of the sale, the chief executive officer now owns 856,381 shares of the company’s stock, valued at approximately $38,742,676.44. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 16,959 shares of company stock worth $773,766. Company insiders own 10.65% of the company’s stock.

About 10x Genomics

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.